FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
News|Articles|April 11, 2026
FDA tracker: Novel approvals in pediatrics during 2026
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Kelly King
A review of 6 novel drugs approved by the FDA, with links to coverage from Contemporary Pediatrics and other MJH Life Sciences brands.
Advertisement
Advertisement
Multiple strides in pediatric care have been reported so far in 2026, marking a transformative year for the treatment of rare pediatric disorders and chronic dermatologic conditions. From the first targeted therapy for neurologic complications in Hunter syndrome and novel interventions for ultrarare diseases such as Menkes disease and arginase 1 deficiency, to historic firsts in oral and topical treatments for plaque psoriasis and atopic dermatitis in children and adolescents, clinical innovation is rapidly expanding the therapeutic tool kit available to pediatricians.
Related to this article
FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.
Phase 3 data show lebrikizumab improved skin clearance, itch, and quality of life in children with moderate-to-severe atopic dermatitis.
FDA granted priority review to Teva's ecopipam for pediatric Tourette syndrome, backed by phase 3 data showing reduced relapse risk.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Advertisement
Advertisement